Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations …
M Suwa, Y Nohara, I Morii, M Kino - Circulation Reports, 2023 - jstage.jst.go.jp
Background: Off-label dosing of direct oral anticoagulants (DOAC) as a treatment for non-
valvular atrial fibrillation (NVAF) is problematic. Here, we investigated the status of …
valvular atrial fibrillation (NVAF) is problematic. Here, we investigated the status of …
Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation―Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration―
M Suwa, I Morii, M Kino - Circulation Journal, 2019 - jstage.jst.go.jp
Background: Practice-based investigations on direct oral anticoagulant (DOAC) treatment for
non-valvular atrial fibrillation (NVAF) have shown that off-label under-dosing is increasingly …
non-valvular atrial fibrillation (NVAF) have shown that off-label under-dosing is increasingly …
Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation based on Blood Coagulation Activity and Drug Plasma Concentration …
M Suwa, I Mori, M Kino, Y Matsui, M Yoshinaga… - 2024 - preprints.org
Background: The safety and effectiveness of factor-Xa (FXa) inhibitors for nonvalvular atrial
fibrillation (NVAF) remains inconclusive. We investigated the current dosing of rivaroxaban …
fibrillation (NVAF) remains inconclusive. We investigated the current dosing of rivaroxaban …
Direct oral anticoagulant (DOAC) dosing in patients with non-valvular atrial fibrillation (NVAF) in the United Kingdom: a retrospective cohort study using CPRD Gold …
A Khachatryan, IU Doobaree, G Spentzouris… - Advances in …, 2023 - Springer
Introduction Per-label dosing of direct oral anticoagulants (DOACs) is important for the
prevention of stroke and systemic embolism among patients with non-valvular atrial …
prevention of stroke and systemic embolism among patients with non-valvular atrial …
Interpatient variation in rivaroxaban and apixaban plasma concentrations in routine care
M Gulilat, A Tang, SE Gryn, P Leong-Sit… - Canadian Journal of …, 2017 - Elsevier
Background Direct-acting oral anticoagulants (DOACs) are widely prescribed for stroke
prevention in patients with atrial fibrillation (AF). An important advantage of DOACs is that …
prevention in patients with atrial fibrillation (AF). An important advantage of DOACs is that …
Routine coagulation tests in patients with nonvalvular atrial fibrillation under dabigatran and rivaroxaban therapy: an affordable and reliable strategy?
Dabigatran and rivaroxaban, direct oral anticoagulants (DOACs), affect coagulation tests,
and knowledge of their effects is important for therapeutic monitoring. Our aim was to …
and knowledge of their effects is important for therapeutic monitoring. Our aim was to …
Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation
S Perreault, R Cote, A Dragomir, B White-Guay… - Plos one, 2022 - journals.plos.org
Background Low-dose direct oral anticoagulant (DOAC) use is quite prevalent in clinical
practice, but evidence of its effectiveness and safety compared with high-dose DOAC in …
practice, but evidence of its effectiveness and safety compared with high-dose DOAC in …
Intra-and inter-individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation
M Miklič, A Mavri, N Vene, L Söderblom… - European Journal of …, 2019 - Springer
Background Routine laboratory monitoring of rivaroxaban and dose adjustment relating to
exposure is currently not recommended. However, in certain clinical situations, assessment …
exposure is currently not recommended. However, in certain clinical situations, assessment …
Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation
T Yamashita, Y Koretsune, M Yasaka, H Inoue… - Circulation …, 2012 - jstage.jst.go.jp
Background: Edoxaban is a once-daily (QD) oral, direct factor Xa inhibitor in clinical
development for the prevention of stroke in patients with non-valvular atrial fibrillation …
development for the prevention of stroke in patients with non-valvular atrial fibrillation …
Initial rivaroxaban dosing in patients with atrial fibrillation
K Ablefoni, A Buchholz, L Ueberham… - Clinical …, 2019 - Wiley Online Library
Background Rivaroxaban is a non‐vitamin K oral anticoagulant and has been approved for
prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation …
prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation …
相关搜索
- atrial fibrillation effectiveness and safety
- atrial fibrillation rivaroxaban dosing
- plasma concentration efficacy and safety
- plasma concentration rivaroxaban or apixaban
- efficacy and safety rivaroxaban or apixaban
- atrial fibrillation bleeding risk
- atrial fibrillation low dose
- plasma levels fibrillation patients
- atrial fibrillation apixaban in patients
- plasma concentrations interpatient variation
- plasma concentrations routine care
- atrial fibrillation dosage strategy
- atrial fibrillation meta analysis
- atrial fibrillation comparisons of effectiveness